Thrombopoietin receptor agonists, such as romiplostim 1 to 10 mcg / kg subcutaneously once a week, eltrombopag 25 to 75 mg orally once a day, and avatrombopag 20 mg orally once a dayy have response rates > 85%. TPO-RAs often need to be administered continuously to maintain the platelet count > 50, 000 / mcL (> 50 × 10 9 / L), but data suggest that one third of adults will undergo a treatment-free remission after 1 year and > 50% after 2 years.